HBI Deals+Insights / Interviews
Demand for GLP-1 receptor agonists (the class of drugs used to treat obesity and diabetes) has been growing rapidly, opening up more and more opportunities in the market, such as ‘holistic’ online prescription services. We’ve seen both the positives and negatives of the use of GLP-1 RAs in the US and Europe, from transforming people’s health for the better to misuse and inappropriate supply. But what do we know about the market in the Middle East?